Nelly Mugo, MBChB, MMed, MPH

Research Associate Professor, Global Health

Prof. Nelly R. Mugo is an associate research professor in the Department of Global Health at the University of Washington, a senior principal clinical research scientist at the Kenya Medical Research Institute (KEMRI), and a reproductive health specialist with three decades of work experience. Her research focus has been on the prevention of HIV and cervical cancer among other reproductive health research work.  She has been an investigator on two landmark clinical trials, the Partners PrEP study that contributed evidence to inform the change of indication for use of Truvada as HIV prevention pre-exposure prophylaxis (PrEP) and a protocol lead for the ongoing ‘Kenya Single-dose HPV Vaccine-Efficacy (KEN SHE) Study –’ that has provided evidence on the efficacy of single-dose HPV vaccination. She is a member of the International Papillomavirus Society education committee, and the Kenya Obstetrics and Genecology society and has contributed to several World Health Organization and Kenya ministry of health working group scientific committees. She is widely published in peer review journals.

Publications

  1. Segawa, I, Wu, L, Odoyo, J, Mwangi, M, Morton, JF, Irungu, E et al.. High adherence to oral daily PrEP in a real-world implementation project in Kenya: a brief communication. AIDS Res Ther. 2026; :. doi: 10.1186/s12981-026-00875-4. PubMed PMID:41877166 .
  2. Umutesi, G, Weiner, BJ, Jewell, T, Kapiga, S, Lane, J, Mugo, NR et al.. A framework policy analysis of single-dose HPV vaccination adoption in East Africa: a rapid review. BMC Health Serv Res. 2026; :. doi: 10.1186/s12913-026-14336-1. PubMed PMID:41862937 .
  3. Rockstroh, JK, Kassim, S, Paredes, R, Bettacchi, C, Sinclair, G, Avihingsanon, A et al.. Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. Lancet HIV. 2026; :. doi: 10.1016/S2352-3018(26)00033-0. PubMed PMID:41763226 .
  4. Adhiambo, HF, Thomas, K, Coe, MM, Oluoch, L, Ihaji, V, Kerubo, MB et al.. Applying FRAME-IS to characterize provider-led adaptations to a cervical cancer prevention intervention in Kenya. Implement Sci Commun. 2026; :. doi: 10.1186/s43058-026-00883-5. PubMed PMID:41731591 .
  5. Kiptinness, C, Mureithi, MW, Osoti, A, Wairimu, N, Githuku, DM, Okello, P et al.. Acceptability of secondary distribution of HIV self-testing kits in central Kenya: a qualitative study on the perspectives of people living with HIV, their sexual partners, and healthcare providers. AIDS Care. 2025; :1-11. doi: 10.1080/09540121.2025.2605486. PubMed PMID:41416962 .
Search PubMed